There are 468 papers on postoperative cognitive dysfunction in aging research: 98 trials and 103 observational studies in people, 185 in animals, 69 reviews.
468 papers study it128 more mention it335 findings
12 new papers in 30 daysSee all 596 papers on postoperative cognitive dysfunction
“On the first day after surgery, there was a lot less cognitive dysfunction in the Dex group than in the controls (odds ratio [OR] = 0.25, 95% CI: 0.15~0.42, P<0.001).”
- Human trial98
- Humans103
- Animals185
Interventions
44Dexmedetomidine
downin humans14no changein humans2downin mice1OR 0.26
16 studies
Dexmedetomidine
downin humans14no changein humans2downin mice1OR 0.26
Dexmedetomidine decreases postoperative cognitive dysfunction in humans (all doses (low, medium and high) compared with normal saline control).
“all doses of Dex reduced the incidence of Postoperative cognitive dysfunction (POCD)”
Human trialall doses (low, medium and high) compared with normal saline controlfemalesn = 165
Frontiers in surgery
Dexmedetomidine decreases postoperative cognitive dysfunction in humans (elderly patients undergoing radical colon cancer surgery under general anesthesia).
“a lower incidence of cognitive dysfunction on the 1st and 5th postoperative days”
Human trialelderly patients undergoing radical colon cancer surgery under general anesthesiapostoperative days 1 and 5n = 117
World journal of gastrointestinal surgery
Dexmedetomidine showed no clear effect on postoperative cognitive dysfunction in humans (assessed at 7, 30 and 90 days postoperatively).
“When the patients were assessed 7 days, 30 days, and 90 days postoperatively, there was no significant difference in POCD incidence among the three groups.”
Human trialassessed at 7, 30 and 90 days postoperatively7, 30 and 90 daysn = 90
Journal of cardiothoracic surgery
Dexmedetomidine decreases postoperative cognitive dysfunction in humans (10.0% vs. 40.0%).
“significantly lower than that in the PS (combined anesthetization with propofol and sevoflurane) group, 1 day post-surgery (10.0% vs. 40.0%, P = 0.008)”
Human trialadded to propofol, remifentanil and sevoflurane anesthesia, compared with propofol-sevoflurane (PS) group1 day post-surgeryn = 90
Journal of cardiothoracic surgery
Dexmedetomidine showed no clear effect on postoperative cognitive dysfunction in humans (13.3% vs. 10.0%).
“Patients in Group PS had a higher incidence of POCD than patients in the Group PSD at the corresponding time point (40.0% vs. 10.0%, P = 0.008); the different incidences of POCD between Group P and Group PSD showed no significant difference (13.3% vs. 10.0%; P = 0.690).”
Human trialn = 90
Journal of cardiothoracic surgery
Dexmedetomidine protects against postoperative cognitive dysfunction in humans (versus saline control).
“compared to the saline group, both groups had higher MMSE and MoCA scores and decreased incidences of POCD”
Human trialversus saline control
Frontiers in aging neuroscience
Dexmedetomidine decreases postoperative cognitive dysfunction in humans (versus normal saline control; cataract surgery under peribulbar block) (significant decline in patients developing POCD, P < 0.0001).
“In comparison with control group, ketamine and dexmedetomidine groups exhibited a significant decline in number of patients who developed POCD (P < 0.0001)”
Human trialversus normal saline control; cataract surgery under peribulbar block0.5 μg/kg/h
Indian journal of anaesthesia
Dexmedetomidine decreases postoperative cognitive dysfunction in humans (compared with placebo).
“Pairwise and network meta-analysis showed dexmedetomidine was significantly reducing the incidence of POCD when compared with placebo.”
Human trialcompared with placebo
International journal of surgery (London, England)
Dexmedetomidine showed no clear effect on postoperative cognitive dysfunction in humans (compared with lidocaine) (29.03% lidocaine vs 24.1% dexmedetomidine, P = 0.77).
“There was no significant difference in the incidence of POCD”
Human trialcompared with lidocaine
Anaesthesiology intensive therapy
Dexmedetomidine showed no clear effect on postoperative cognitive dysfunction in humans (compared to lidocaine) (24.1% vs 29.03%).
“Nine patients (29.03%) in the lidocaine group and 7 patients (24.1%) in the dexmedetomidine group showed an increase of ≥ 20% in the test scores in > 2 tests and satisfied the predetermined criteria for diagnosis of POCD on postoperative day 3.”
Human trialcompared to lidocainepostoperative day 3n = 64
Anaesthesiology intensive therapy
All 19Fewer
Esketamine
no changein humans2downin mice2RR 0.47
4 studies
Esketamine
no changein humans2downin mice2RR 0.47
Esketamine showed no clear effect on postoperative cognitive dysfunction in elderly patients undergoing thoracoscopic lobectomy (RD, −22.5%; 95% CI, −44.8% to −0.2%).
“The overall incidence of POCD in this trial was 31.3%, including 8 (20%) patients in Group F and 17 (42.5%) patients in Group C (RD, −22.5%; 95% CI, −44.8% to −0.2%; P = 0.054).”
Human trialin elderly patients undergoing thoracoscopic lobectomythree daysn = 80
Drug design, development and therapy
Esketamine showed no clear effect on postoperative cognitive dysfunction in humans (elderly patients undergoing thoracoscopic lung cancer surgery) (20% vs 42.5%, RR 0.47 (95% CI 0.24 to 0.92), p = 0.054).
“Esketamine-based OFA did not significantly reduce POCD incidence”
Human trialelderly patients undergoing thoracoscopic lung cancer surgerywithin 3 daysn = 80
Drug design, development and therapy
Esketamine showed no clear effect on postoperative cognitive dysfunction in humans.
“The incidence of dNCR at 7 days after surgery was lower in group S, compared with patients in group C (P<0.05); however, the incidence of POCD 3 months after surgery was similar in both groups (P>0.05).”
Human trial5min before the beginning of the surgeryn = 67
Drug design, development and therapy
Esketamine showed no clear effect on postoperative cognitive dysfunction in humans (undergoing gastrointestinal surgery under general anesthesia) (6.06% vs 14.37% P=0.247).
“there was no difference in both groups regarding POCD 3 months postoperatively (6.06% vs 14.37% P=0.247).”
Human trialundergoing gastrointestinal surgery under general anesthesiaintravenous0.15 mg/kg3 months postoperativelyn = 84
Drug design, development and therapy
Esketamine decreases postoperative cognitive dysfunction in mice after exploratory laparotomy under isoflurane anesthesia.
“intraperitoneal administration of esketamine could alleviate POCD, as demonstrated through a suite of behavioral tests.”
Animalsafter exploratory laparotomy under isoflurane anesthesia10 mg/kg
Neurochemical research
Esketamine protects against postoperative cognitive dysfunction in mice (aged POCD mouse model).
“Our findings showed that esketamine effectively mitigated POCD in aged mice.”
Animalsaged POCD mouse model
The Kaohsiung journal of medical sciences
Ulinastatin
downin humans4OR 0.28
4 studies
Ulinastatin
downin humans4OR 0.28
Ulinastatin prevents postoperative cognitive dysfunction in humans (compared with dexmedetomidine) (OR = 0.28, 95% CI 0.10 to 0.71).
“ulinastatin may be more effective in preventing POCD than dexmedetomidine [odds ratio (OR) = 0.28, 95% confidence interval (CI) = (0.10, 0.71)]”
Human trialcompared with dexmedetomidine
Brain and behavior
Ulinastatin decreases postoperative cognitive dysfunction in humans (elderly patients undergoing spinal surgery; total intravenous anesthesia) (16% vs. 43%, χ2 = 5.079, P = 0.024).
“Ulinastatin infusion significantly reduced the incidence of POCD in elderly patients undergoing spine surgery”
Human trialelderly patients undergoing spinal surgery; total intravenous anesthesia10,000 units/kg then 5000 units/kg
Frontiers in pharmacology
Ulinastatin decreases postoperative cognitive dysfunction in humans after one-lung ventilation surgery with neoadjuvant chemotherapy (23.7% vs 45.9% incidence).
“The U group had a lower incidence of POCD than C group (23.7 % versus 45.9 %, P = 0.043).”
Human trialafter one-lung ventilation surgery with neoadjuvant chemotherapy10,000 U/kg before anesthesia, then 5000 U/kg dailypostoperative days 1 to 3n = 80
Metabolic brain disease
Ulinastatin prevents postoperative cognitive dysfunction in humans (perioperative use in elderly patients under general anesthesia).
“effectively prevent the occurrence of POCD and reduce its incidence”
Reviewperioperative use in elderly patients under general anesthesia
Medicine
Parecoxib
downin humans2no changein humans1
2 studies
Parecoxib
downin humans2no changein humans1
Parecoxib showed no clear effect on postoperative cognitive dysfunction in humans (at 3-month follow-up after total knee arthroplasty) (9.7% vs 6.7%).
“no significant difference was found between groups C and P at 3-month follow-up (9.7% vs 6.7%)”
Human trialat 3-month follow-up after total knee arthroplastyparecoxib sodium3 months
Medicine
Parecoxib decreases postoperative cognitive dysfunction in humans (at 1 week after total knee arthroplasty) (16.7% vs 33.9%).
“POCD incidence in group P was significantly lower compared with that of group C at 1 week after surgery (16.7% vs 33.9%; P < 0.05)”
Human trialat 1 week after total knee arthroplastyparecoxib sodium1 week
Medicine
Parecoxib decreases postoperative cognitive dysfunction in humans (perioperative use compared with control).
“perioperative intravenous parecoxib could remarkably reduce the incidence of POCD”
Reviewperioperative use compared with controln = 1,106
Expert review of clinical pharmacology
Propofol
downin humans1no changein humans1
2 studies
Propofol
downin humans1no changein humans1
Propofol showed no clear effect on postoperative cognitive dysfunction in humans (compared with dexmedetomidine and midazolam sedation; assessed 1 year after surgery) (14.0%, 10.6% and 14.9% across the three groups).
“the incidence of POCD was not significantly different among the 3 groups (14.0%, 10.6% vs. 14.9%, χ = 0.016 and 0.382, P = 0.899 and 0.536)”
Human trialcompared with dexmedetomidine and midazolam sedation; assessed 1 year after surgery1 year
Chinese medical journal
Propofol decreases postoperative cognitive dysfunction in humans (compared with inhaled anesthetic agents).
“The most evident finding was that propofol attenuated POCD compared to inhaled anesthetic agents.”
Reviewcompared with inhaled anesthetic agents
Impact of Ketamine and Propofol on Cognitive Function in Elderly Patients: A Systematic Review
Cureus
Ketamine
downin humans2
2 studies
Ketamine
downin humans2
Ketamine prevents postoperative cognitive dysfunction in humans (efficiency ranking in the network meta-analysis).
“The efficiency ranking results also find that ulinastatin and ketamine might provide better effects regarding POCD prevention.”
Human trialefficiency ranking in the network meta-analysis
Brain and behavior
Ketamine decreases postoperative cognitive dysfunction in humans (versus normal saline control; cataract surgery under peribulbar block) (significant decline in patients developing POCD, P < 0.0001).
“In comparison with control group, ketamine and dexmedetomidine groups exhibited a significant decline in number of patients who developed POCD (P < 0.0001)”
Human trialversus normal saline control; cataract surgery under peribulbar block0.3 mg/kg/h
Indian journal of anaesthesia
High-fat diet
upin mice2
2 studies
High-fat diet
upin mice2
High-fat diet increases postoperative cognitive dysfunction in mice after isoflurane exposure and tibial fracture surgery.
“An HFD exacerbates POCD in older mice.”
Animalsafter isoflurane exposure and tibial fracture surgerymales
Nutritional neuroscience
High-fat diet increases postoperative cognitive dysfunction in mice with sevoflurane anesthesia and exploratory surgery.
“HFD can aggravate POCD in aged C57BL/6 mice”
Animalswith sevoflurane anesthesia and exploratory surgery8 weeksmales
High-fat diet aggravates postoperative cognitive dysfunction in aged mice
BMC anesthesiology
Multidomain intervention
no changein humans1
1 study
Multidomain intervention
no changein humans1
Multidomain intervention showed no clear effect on postoperative cognitive dysfunction in humans (8.0% vs 24.0%).
“The incidence of POCD in the control group (24.0%) was relatively higher in the control group than that in the experimental group (8.0%), but there was no significant difference between the two groups.”
Human trial14 days after the operationn = 50
International journal of general medicine
Multidomain intervention showed no clear effect on postoperative cognitive dysfunction in humans after total hip arthroplasty (without statistical significance).
“The incidence of POCD in the experimental group was lower and its duration was shorter than in the control group but without statistical significance.”
Human trialafter total hip arthroplastyn = 50
International journal of general medicine
Epidural anesthesia
downin humans1
1 study
Epidural anesthesia
downin humans1
Epidural anesthesia decreases postoperative cognitive dysfunction in humans (combined with general anesthesia versus general anesthesia alone in liver cancer surgery) (P < 0.05).
“There was no significant difference in the score between the two groups before operation and 3 days and 7 days after operation (P > 0.05), while the score was significantly better in the joint group than that in the GA group at 6 hours and 1 day after operation (P < 0.05).”
Human trialcombined with general anesthesia versus general anesthesia alone in liver cancer surgery
Journal of oncology
Epidural anesthesia decreases postoperative cognitive dysfunction in humans (undergoing liver cancer surgery).
“combined epidural anesthesia and general anesthesia can significantly reduce postoperative cognitive dysfunction and inhibit postoperative stress responses in elderly patients undergoing liver cancer surgery.”
Human trialundergoing liver cancer surgeryn = 115
Journal of oncology
Methoxamine
no changein humans1upin humans1
1 study
Methoxamine
no changein humans1upin humans1
Methoxamine showed no clear effect on postoperative cognitive dysfunction in humans (2–3 μg·kg−1·min−1 during epidural anesthesia) (M1 6.7% and M2 6.7% vs control 5.3%).
“Intravenous infusion of methoxamine at 2-3 μg·kg−1·min−1 can maintain stable hemodynamics in elderly patients during epidural anesthesia for hip-joint replacement surgery, without increasing the incidence of POCD.”
Human trial2–3 μg·kg−1·min−1 during epidural anesthesia2–3 μg·kg−1·min−1during surgeryn = 300
BMC anesthesiology
Methoxamine increases postoperative cognitive dysfunction in humans (4 μg·kg−1·min−1 (M3 group) versus control) (18.7% vs 5.3% control incidence).
“the incidence of POCD, which was higher in the M3 group (18.7%) than in the control group (5.3%)”
Human trial4 μg·kg−1·min−1 (M3 group) versus control4 μg·kg−1·min−1during surgeryn = 300
BMC anesthesiology
Etomidate
downin humans1
1 study
Etomidate
downin humans1
Etomidate decreases postoperative cognitive dysfunction in humans (8.3% POCD rate on day 1 in the medium-dose group).
“Etomidate 0.2 mg/kg with nerve block achieves favorable hemodynamics and minimizes POCD and adverse reactions in elderly hernia surgery”
Human trialhernia surgery with nerve block, sufentanil, and remimazolam; compared with low- and high-dose etomidate0.2 mg/kgpostoperative day 1n = 36
The Annals of pharmacotherapy
Electroacupuncture + dexmedetomidine
downin humans1
1 study
Electroacupuncture + dexmedetomidine
downin humans1
Electroacupuncture + dexmedetomidine decreases postoperative cognitive dysfunction in humans (at 1 month after hip or knee arthroplasty) (10% vs 30% (EA group) and 32.5% (Dex group)).
“The incidence of POCD was significantly lower in the EA+Dex group (10%) compared with the EA group (30%) and the Dex group (32.5%) (p < 0.05).”
Human trialat 1 month after hip or knee arthroplasty1 month
Complementary medicine research
Multimodal prehabilitation
no changein humans1OR 1.37
1 study
Multimodal prehabilitation
no changein humans1OR 1.37
Multimodal prehabilitation showed no clear effect on postoperative cognitive dysfunction in humans (cardiac surgery) (OR 1.37, 95% CI 0.54-3.50, P = 0.52).
“a 4-6-week multimodal prehabilitation program did not reduce postoperative cognitive dysfunction 3 months after cardiac surgery”
Human trialcardiac surgery4-6 weeksn = 116
Journal of clinical anesthesia
Transcutaneous auricular vagus nerve stimulation
downin humans1
1 study
Transcutaneous auricular vagus nerve stimulation
downin humans1
Transcutaneous auricular vagus nerve stimulation decreases postoperative cognitive dysfunction in humans (compared with sham stimulation) (10.2% vs 32.7%; χ2 = 7.498, p = 0.006).
“The incidence of POCD in the taVNS group was significantly lower than that in the sham group (10.2% vs 32.7%, χ2 = 7.498, p = 0.006).”
Human trialcompared with sham stimulationto postoperative day 7n = 103
Neuromodulation : journal of the International Neuromodulation Society
Ambient temperature
no changein humans1
1 study
Ambient temperature
no changein humans1
Ambient temperature showed no clear effect on postoperative cognitive dysfunction in humans (elderly patients undergoing laparoscopic surgery).
“There were no significant differences in the incidence of POCD on postoperative days 1, 3, and 7 between patients undergoing laparoscopic surgery in winter vs summer.”
Human trialelderly patients undergoing laparoscopic surgery
World journal of psychiatry
All 44Fewer
Effects
5Length of hospital stay
upin humans1
1 study
Length of hospital stay
upin humans1
Postoperative cognitive dysfunction increases length of hospital stay in humans (postcardiac surgery, <30 days postsurgery) (MD 1.37 days (95% CI: 0.35, 2.39)).
“Patients who developed POCD <30 days postcardiac and noncardiac surgeries experienced longer LOS than those who did not [mean difference (MD) = 1.37 days (95% CI: 0.35, 2.39); I2 = 92.38%”
Reviewpostcardiac surgery, <30 days postsurgery
Outcomes associated with postoperative cognitive dysfunction: a systematic review and meta-analysis
Age and ageing
Hospital costs
upin humans1
1 study
Hospital costs
upin humans1
Postoperative cognitive dysfunction is linked with higher hospital costs in humans after surgery (8973.43 USD vs. 5913.62 USD, P < 0.001).
“incur higher hospital costs (8973.43 USD [3481.69, 11 763.74] vs. 5913.62 USD [332.43, 19 567.33]; P < 0.001)”
Humansafter surgery1 weekn = 289
BMC geriatrics
Length of stay
upin humans1
1 study
Length of stay
upin humans1
Postoperative cognitive dysfunction is linked with higher length of stay in humans after surgery (11 days vs. 8 days, P = 0.01).
“patients with POCD were more likely to need a prolonged LOS (11 days [1, 46] vs. 8 days [2, 42]; P = 0.01)”
Humansafter surgery1 weekn = 289
BMC geriatrics
Functional decline
no changein humans1
1 study
Functional decline
no changein humans1
Postoperative cognitive dysfunction was not clearly linked with functional decline in humans after surgery.
“At their 3-month follow-ups, the patients with POCD were not associated with IADL decline.”
Humansafter surgery3 monthsn = 289
BMC geriatrics
Mortality
upin humans1
1 study
Mortality
upin humans1
Postoperative cognitive dysfunction increases mortality in humans.
“POD can lead to postoperative cognitive dysfunction (POCD), a more prolonged cognitive impairment associated with longer length of hospital stay and cost, premature withdrawal from the workforce, and greater 1-year mortality.”
Review1-year
Mind Over Matter? The Hidden Epidemic of Cognitive Dysfunction in the Older Surgical Patient
Annals of surgery
Upstream
15Inflammation
no changein humans1mediatesin humans1
2 studies
Inflammation
no changein humans1mediatesin humans1
Inflammation was not clearly linked with postoperative cognitive dysfunction in older cancer patients undergoing surgery.
“no significant associations were shown between the early surgery-induced inflammatory response and either POCD or decline within the different cognitive domains”
Humansin older cancer patients undergoing surgeryn = 248
Journal of the American Geriatrics Society
Inflammation mediates postoperative cognitive dysfunction in humans.
“Mounting evidence have shown that neuroinflammation plays an essential role in POCD.”
Review
Inflammopharmacology
SIRT1
downin mice1mediatesin mice1
2 studies
SIRT1
downin mice1mediatesin mice1
SIRT1 protects against postoperative cognitive dysfunction in mice (shown by SIRT1 rescue with resveratrol after splenectomy).
“rescue of hippocampal SIRT1 expression ameliorated the cognitive impairment in the elderly mice under splenectomy”
Animalsshown by SIRT1 rescue with resveratrol after splenectomyhippocampusmales
American journal of translational research
SIRT1 mediates postoperative cognitive dysfunction in mice (cardiac surgery-induced POCD, via TLR4/NF-κB pathway).
“SIRT1 mediates the improvement of cardiac surgery-induced postoperative cognitive dysfunction via the TLR4/NF-κB pathway.”
Animalscardiac surgery-induced POCD, via TLR4/NF-κB pathway
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
PRKCD
upin rats1
1 study
PRKCD
upin rats1
PRKCD increases postoperative cognitive dysfunction in rats after SEV exposure; shown by knockdown.
“PRKCD enhanced SEV-induced POCD in aged rats via the regulation of PINK1/PRKN mitophagy pathway”
Animalsafter SEV exposure; shown by knockdown
Journal of cellular and molecular medicine
AMPK-SIRT1 pathway
downin mice1
1 study
AMPK-SIRT1 pathway
downin mice1
AMPK-SIRT1 pathway protects against postoperative cognitive dysfunction in mice (POCD induced by open tibial fracture surgery under isoflurane anesthesia).
“The AMPK/SIRT1 pathway activation mitigated POCD.”
AnimalsPOCD induced by open tibial fracture surgery under isoflurane anesthesia
The international journal of neuropsychopharmacology
Stable shift in microglial identity
mediatesin reviews1
1 study
Stable shift in microglial identity
mediatesin reviews1
stable shift in microglial identity mediates postoperative cognitive dysfunction.
“POCD is driven not by ongoing inflammation, but by a stable shift in microglial identity.”
Review
Frontiers in molecular neuroscience
Sarcopenia
no changein humans1OR 1.07
1 study
Sarcopenia
no changein humans1OR 1.07
Sarcopenia was not clearly linked with postoperative cognitive dysfunction in humans (undergoing non-cardiac surgery under general anaesthesia) (OR 1.070, 95% CI 0.442–2.589).
“POCD (OR: 1.070, 95% CI: 0.442, 2.589, P = 0.880) than non-sarcopenic patients.”
Humansundergoing non-cardiac surgery under general anaesthesian = 117
Indian journal of anaesthesia
NLRP3
upin rats1
1 study
NLRP3
upin rats1
NLRP3 increases postoperative cognitive dysfunction in rats after orthopedic surgery (tibial fracture model).
“NLRP3 activation contributes to POCD development because it is intrinsically involved in mitochondrial dysfunction and oxidative stress after orthopedic surgery in aged rats”
Animalsafter orthopedic surgery (tibial fracture model)males
Metabolic brain disease
HDAC6
upin mice1
1 study
HDAC6
upin mice1
HDAC6 increases postoperative cognitive dysfunction in mice (hippocampal, via NLRP3-induced microglial pyroptosis and HSP90/HSP70).
“Our findings suggest that hippocampal HDAC6 promotes POCD by regulating NLRP3-induced microglia pyroptosis via HSP90/HSP70 in aged mice.”
Animalshippocampal, via NLRP3-induced microglial pyroptosis and HSP90/HSP70hippocampus
Biochimica et biophysica acta. Molecular basis of disease
Apoptosis
mediatesin mice1
1 study
Apoptosis
mediatesin mice1
Apoptosis mediates postoperative cognitive dysfunction in mice (induced by sevoflurane).
“POCD induced by sevoflurane results from ER stress and neuroapoptosis in the hippocampus of aged mice”
Animalsinduced by sevofluranehippocampus
Cellular signalling
ER unfolded protein response
mediatesin mice1
1 study
ER unfolded protein response
mediatesin mice1
ER unfolded protein response mediates postoperative cognitive dysfunction in mice (induced by sevoflurane).
“POCD induced by sevoflurane results from ER stress and neuroapoptosis in the hippocampus of aged mice”
Animalsinduced by sevofluranehippocampus
Cellular signalling
Cytokines
no changein humans1
1 study
Cytokines
no changein humans1
Cytokines showed no clear effect on postoperative cognitive dysfunction in humans.
“No correlation was found between POCD and cytokine levels.”
Human trial
Journal of clinical anesthesia
All 15Fewer
Associations
158Dexmedetomidine
downin humans14mixedin humans1downin reviews1RR 0.47–0.49
15 studies
Dexmedetomidine
downin humans14mixedin humans1downin reviews1RR 0.47–0.49
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (postoperative following major abdominal surgery) (12.5% vs 37.5%).
“The incidence of significant cognitive decline (>5-point fall) was lowest in D1 and D2 (12.5% each) and highest in the placebo group (37.5%, p = 0.048).”
Human trialpostoperative following major abdominal surgery24 hoursn = 72
Cureus
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans.
“The incidence of POCD in the DEX group was lower than that in the control group, with a statistically difference.”
Human trialn = 90
BMC anesthesiology
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (low, medium, and high doses).
“Upon comparing the incidence of POCD was compared between the Dex and saline treatment groups, it was found that the low, medium, and high doses of Dex [0.4, 0.6 and 0.8 μg/(kg·h) Dex, respectively] all effectively the incidence of POCD (P < 0.05).”
Human triallow, medium, and high doses15 min prior to anesthesia induction, followed by postoperative infusions of 0.4, 0.6, and 0.8 μg/(kg·h) Dex to maintain anesthesiafemalesn = 165
Frontiers in surgery
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (postoperative day 1: 11.86% vs 27.59%; day 5: 5.08% vs 18.97%).
“On postoperative days 1 and 5, the incidence of cognitive dysfunction in group A was 11.86% and 5.08%, respectively, while those in group B were 27.59% and 18.97%, respectively; there were significant differences between the two groups (P < 0.05; Table ).”
Human trialn = 117
World journal of gastrointestinal surgery
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (40.0% vs. 10.0%).
“Patients in Group PS had a higher incidence of POCD than patients in the Group PSD at the corresponding time point (40.0% vs. 10.0%, P = 0.008); the different incidences of POCD between Group P and Group PSD showed no significant difference (13.3% vs. 10.0%; P = 0.690).”
Human trialn = 90
Journal of cardiothoracic surgery
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (OR 0.25 (95% CI 0.15–0.42)).
“On the first day after surgery, there was a lot less cognitive dysfunction in the Dex group than in the controls (odds ratio [OR] = 0.25, 95% CI: 0.15~0.42, P<0.001).”
Human trialintraoperative administration, compared with normal saline control; first day after surgeryn = 675
Minerva anestesiologica
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans.
“At 3 days postoperative (T6) and 7 days postoperative (T7), there was no statistically significant difference (p > 0.05) in the incidence of POCD between groups R and D, even though both were lower than the incidence of POCD in group C, which was statistically significant (p < 0.05).”
Human trial
Frontiers in aging neuroscience
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans.
“and the incidence of POCD was lower in the DEX group.”
Human trialn = 82
American journal of translational research
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans.
“Additionally, there was a rise in the number of patients who developed POCD in the control group when compared to ketamine and dexmedetomidine groups (P < 0.0001); however, the ketamine and dexmedetomidine groups did not vary from one another (P = 0.747)..”
Human trialstarted 10 min before the start of surgery and continued throughout the duration of surgeryn = 90
Indian journal of anaesthesia
Dexmedetomidine lowers the risk of postoperative cognitive dysfunction in humans (medium- and high-dose groups compared with saline control) (significantly lower than control group (P < 0.05)).
“The incidences of POCD in medium- and high-dose DEX groups were comparable but significantly lower than that in the control group (P < 0.05).”
Human trialmedium- and high-dose groups compared with saline controlmedium and high maintenance doses
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
All 16Fewer
Transcutaneous electrical acupoint stimulation
downin humans6RR 0.55
6 studies
Transcutaneous electrical acupoint stimulation
downin humans6RR 0.55
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans.
“The POCD incidence in the TEAS group was significantly lower than that in the control group (P = 0.028).”
Human trialn = 40
Journal of orthopaedic surgery and research
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans (postoperative total knee arthroplasty) (10% vs 40%).
“The incidence of POCD in the TEAS group was 10%, lower than in the control group (40%) (P < 0.05).”
Human trialpostoperative total knee arthroplastyn = 40
Journal of orthopaedic surgery and research
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans (20% vs 65.4% on day 1, 7.3% vs 43.6% on day 7, and 3.6% vs 40% on day 30).
“Following the study procedure, the incidence of POCD in the sham-TEAS group was always significantly higher than in the TEAS group (postoperative day 1: 65.4% vs 20%, postoperative day 7: 43.6% vs 7.3%, and postoperative day 30: 40% vs 3.6%, all P < 0.001).”
Human trialfrom 30 min before anesthesia induction until the end of the surgeryn = 110
Heliyon
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans after thoracoscopic pulmonary resection for lung cancer (20% vs 65.4% at day 1, 7.3% vs 43.6% at day 7, 3.6% vs 40% at day 30, all P < 0.001).
“the incidence of POCD in the sham-TEAS group was always significantly higher than in the TEAS group (65.4% vs 20%, 43.6% vs 7.3%, 40% vs 3.6%, all P < 0.001).”
Human trialafter thoracoscopic pulmonary resection for lung cancern = 128
Heliyon
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans (22% and 18.4% vs 43.7%).
“On the 3rd day after the operation, POCD occurred in 11 (22%), 9 (18.4%) and 21 (43.7%) patients in groups A, B, and C, respectively, and there was no significant difference between groups A and B (P = 0.616).”
Human trialup to 7 days after the surgeryn = 147
Frontiers in aging neuroscience
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in older patients with lumbar spine surgery (18.3% or 22.4% vs 42.9%).
“Perioperative TEAS intervention could reduce the level of inflammatory factors IL-6, TNF-α in the blood of older patients with lumbar spine surgery, and reduce the incidence of POCD.”
Human trialin older patients with lumbar spine surgery
Frontiers in aging neuroscience
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans (gastrointestinal tumor surgery under general anesthesia) (21.88% vs 40.63%).
“The incidence of POCD in the TEAS group (21.88%) was lower than those in the sham TEAS group (40.63%).”
Human trialgastrointestinal tumor surgery under general anesthesia
Trials
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans (hip replacement surgery) (RR: 0.55, 95% CI: 0.41, 0.73, P<0.001).
“along with a lower postoperative cognitive dysfunction rate (RR: 0.55, 95% CI: 0.41, 0.73, P<0.001).”
Reviewhip replacement surgery
PloS one
Transcutaneous electrical acupoint stimulation lowers the risk of postoperative cognitive dysfunction in humans after general anesthesia (p<0.00001).
“TEAS reduced POCD incidence on the 1st and 3rd but not on the 5th and 7th postoperative days (p<0.00001; p<0.00001; p = 0.20; p = 0.30).”
Reviewafter general anesthesia1st and 3rd postoperative days
Geriatric nursing (New York, N.Y.)
Propofol
downin humans3upin humans1RR 0.37
4 studies
Propofol
downin humans3upin humans1RR 0.37
Propofol lowers the risk of postoperative cognitive dysfunction in humans (compared with dexmedetomidine and midazolam sedation; assessed 7 days after surgery) (18.2% vs 40.0% (dexmedetomidine) and 51.9% (midazolam)).
“POCD incidence in propofol group was significantly lower than that in dexmedetomidine and midazolam groups (18.2% vs. 40.0%, 51.9%, χ = 6.342 and 13.603, P = 0.012 and < 0.001)”
Human trialcompared with dexmedetomidine and midazolam sedation; assessed 7 days after surgery7 days
Chinese medical journal
Propofol lowers the risk of postoperative cognitive dysfunction in humans (compared with isoflurane and sevoflurane, on postoperative days 1 and 3) (P<0.001 vs isoflurane at D1 and D3; P=0.012 (D1) and P=0.013 (D3) vs sevoflurane).
“The incidence of POCD was significantly lower in the propofol group compared to the isoflurane group and the sevoflurane group at D1 and D3”
Human trialcompared with isoflurane and sevoflurane, on postoperative days 1 and 3
Journal of clinical anesthesia
Propofol is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing surgery with general anesthesia) (aHR 1.16, 95% CI 1.09–1.24).
“Long-term cognitive dysfunction (aHR 1.16, 95% CI 1.09–1.24) and long-term mortality (aHR 1.23, 95% CI 1.17–1.29) were also increased.”
Humansundergoing surgery with general anesthesia180–365 daysn = 91,046
Critical care (London, England)
Propofol lowers the risk of postoperative cognitive dysfunction in humans (noncardiac surgery) (RR 0.37, 95% CI 0.15-0.88).
“The incidence of POCD on postoperative Days 2-6 after propofol anaesthesia was markedly lower than that after inhalation anaesthesia (risk ratio (RR): 0.37, 95% confidence interval (CI): 0.15-0.88, P = .025)”
Reviewnoncardiac surgerypostoperative Days 2-6
Medicine
Insulin
downin humans3
3 studies
Insulin
downin humans3
Insulin lowers the risk of postoperative cognitive dysfunction in humans (4 (13.3%) vs. 12 (38.7%)).
“The insulin group had a significantly lower POCD rate compared with the control group at postoperative day 7 [4 (13.3%) vs. 12 (38.7%), p = 0.024].”
Human trialintranasalstarting 2 days before surgery until 1 h before admission to the operating roomn = 61
Frontiers in aging neuroscience
Insulin lowers the risk of postoperative cognitive dysfunction in humans after laparoscopic radical resection of colorectal cancer (4(13.3%) vs. 12 (38.7%)).
“The insulin group had a significantly lower POCD rate compared with the control group at postoperative day 7 [4(13.3%) vs. 12 (38.7%), p = 0.024].”
Human trialafter laparoscopic radical resection of colorectal cancerpostoperative 7 daysn = 61
Frontiers in aging neuroscience
Insulin lowers the risk of postoperative cognitive dysfunction in humans (metabolic syndrome undergoing noncardiac surgery) (20.8% vs 45.1% (P = 0.008)).
“POCD occurred in the insulin group on the 7th postoperative day in 11 (20.8%) patients, which was fewer than the 23 (45.1%) patients in the placebo group (P = 0.008).”
Human trialmetabolic syndrome undergoing noncardiac surgery40 IU7 daysn = 116
Aging clinical and experimental research
Insulin lowers the risk of postoperative cognitive dysfunction in humans (postoperative).
“reduced incidence of postoperative cognitive dysfunction are demonstrated”
Reviewpostoperative
Consilium Medicum
Sevoflurane
downin humans2upin humans1
3 studies
Sevoflurane
downin humans2upin humans1
Sevoflurane lowers the risk of postoperative cognitive dysfunction in humans (high vs low end-tidal concentration) (10.00% vs 24.59%).
“The incidence of POCD in the high-concentration group was 10.00% (6/60), which was significantly lower than the 24.59% (15/61) observed in the low-concentration group (χ2 = 4.489, P = 0.034).”
Human trialhigh vs low end-tidal concentrationn = 121
Frontiers in aging neuroscience
Sevoflurane lowers the risk of postoperative cognitive dysfunction in humans (abdominal surgery) (10.00% vs. 24.59%).
“The high-concentration group had longer recovery times but a lower incidence of POCD (10.00% vs. 24.59%)”
Human trialabdominal surgery1.5-2.0 MAC vs 0.8-1.2 MACn = 121
Frontiers in aging neuroscience
Sevoflurane raises the risk of postoperative cognitive dysfunction in humans (sevoflurane anesthesia for esophageal carcinoma resection).
“The POCD incidence was higher in elderly patients receiving sevoflurane anesthesia”
Human trialsevoflurane anesthesia for esophageal carcinoma resection
Journal of cancer research and therapeutics
Sevoflurane lowers the risk of postoperative cognitive dysfunction in humans (compared with isoflurane, on postoperative day 1 only; not significant on day 3) (P=0.041 at D1).
“The incidence of POCD was significantly lower in the sevoflurane group compared to the isoflurane group at D1 (P=0.041)”
Human trialcompared with isoflurane, on postoperative day 1 only; not significant on day 3
Journal of clinical anesthesia
Esketamine
downin humans3
3 studies
Esketamine
downin humans3
Esketamine lowers the risk of postoperative cognitive dysfunction in humans (undergoing laparoscopic radical prostatectomy).
“MMSE scores at 1 and 7 days post surgery were higher, and POCD incidence was lower (P < 0.05).”
Human trialundergoing laparoscopic radical prostatectomyn = 186
Journal of visualized experiments : JoVE
Esketamine lowers the risk of postoperative cognitive dysfunction in humans (11.4% versus 31.8% on day 1, 0.0% versus 13.6% on day 3).
“Notably, the incidence of POCD on days 1 (11.4% versus 31.8%, p < 0.05) and 3 (0.0% versus 13.6%, p < 0.05, Table ) after the surgery were significantly lower in the esketamine group than in the control group.”
Human trialinfused until 30 min before the end of the surgeryn = 102
Actas espanolas de psiquiatria
Esketamine lowers the risk of postoperative cognitive dysfunction in humans (pulmonary lobectomy).
“the esketamine group exhibited a significantly lower incidence of POCD on days 1 and 3 postoperatively than the control group”
Human trialpulmonary lobectomy0.3 mg/kg/h
Actas espanolas de psiquiatria
Esketamine is linked with a lower risk of postoperative cognitive dysfunction in humans (elective thoracic surgery) (18.7% vs. 36.0%, P < 0.05).
“reduced POCD at 1 month (18.7% vs. 36.0%, P < 0.05) and 6 months (10.7% vs. 21.3%, P < 0.05)”
Humanselective thoracic surgery1 month post-surgeryn = 140
Journal of cardiothoracic surgery
Frailty
upin humans2upin rats1OR 5.38
3 studies
Frailty
upin humans2upin rats1OR 5.38
Frailty is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing elective surgery).
“Factors significantly associated with POCD (p < 0.05) included age, ASA III classification, female gender, major surgeries, frailty, preoperative depression, type of anesthesia, intraoperative hypotension and blood loss”
Humansundergoing elective surgery
BMC geriatrics
Frailty is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing non-cardiac surgery under general anaesthesia) (OR 5.380, 95% CI 1.718–16.685).
“5.8 times higher risk of POCD (OR: 5.380, 95% CI: 1.718, 16.685, P = 0.004) compared to non-frail counterparts.”
Humansundergoing non-cardiac surgery under general anaesthesian = 117
Indian journal of anaesthesia
Frailty is associated with postoperative cognitive dysfunction in rats after general anaesthesia; frailty induced by hind limb immobilisation (Y-maze alternation ratio 65% ± 37% vs 29% ± 28%, p = 0.01).
“Frailty was significantly associated with POCD.”
Animalsafter general anaesthesia; frailty induced by hind limb immobilisationtwo days after general anaesthesiamalesn = 20
International journal of medical sciences
Hypertension
upin humans3OR 4.153
3 studies
Hypertension
upin humans3OR 4.153
Hypertension is linked with a higher risk of postoperative cognitive dysfunction in humans (elderly patients undergoing oromaxillofacial malignancy surgery) (OR = 4.153, 95% CI: 1.355-12.732).
“hypertension (OR = 4.153, 95% CI: 1.355-12.732), sleep disorders (OR = 1.272, 95% CI: 1.001-1.617), prolonged anesthesia time (OR = 1.009, 95% CI: 1.001-1.018)”
Humanselderly patients undergoing oromaxillofacial malignancy surgeryn = 112
Perioperative medicine (London, England)
Hypertension is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing surgery for oral malignancies) (OR 4.153, 95% CI 1.335-12.732).
“hypertension (OR = 4.153, 95% CI 1.335-12.732, P < 0.05)”
Humansundergoing surgery for oral malignanciesn = 112
Perioperative medicine (London, England)
Hypertension is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing surgery for oral malignancies) (OR 4.153, 95% CI 1.335-12.732).
“hypertension (OR=4.153, 95%CI1.335-12.732, P<0.05)”
Humansundergoing surgery for oral malignanciesn = 112
Research SquarePreprint
Age
upin humans3OR 1.269
3 studies
Age
upin humans3OR 1.269
Age is linked with a higher risk of postoperative cognitive dysfunction in humans (elderly patients undergoing oromaxillofacial malignancy surgery) (OR = 1.269, 95% CI: 1.056-1.525).
“Multivariable logistic regression identified older age (OR = 1.269, 95% CI: 1.056-1.525), lower education level (OR = 0.792, 95% CI: 0.644-0.974), hypertension (OR = 4.153, 95% CI: 1.355-12.732)”
Humanselderly patients undergoing oromaxillofacial malignancy surgeryn = 112
Perioperative medicine (London, England)
Age is associated with postoperative cognitive dysfunction in humans (cardiac surgery with CPB) (63 [58–68] vs. 59 [52–65] years, p = 0.026).
“Patients who developed POCD were significantly older than those without POCD (median (interquartile range [IQR]): 63 [58–68] vs. 59 [52–65] years; p = 0.026).”
Humanscardiac surgery with CPBn = 74
The Heart Surgery Forum
Age is linked with a higher risk of postoperative cognitive dysfunction in humans (undergoing surgery for oral malignancies) (OR 1.269, 95% CI 1.056-1.525).
“Multiple factor logistic regression analysis revealed that age (OR=1.269, 95%CI 1.056-1.525, P<0.05)”
Humansundergoing surgery for oral malignanciesn = 112
Research SquarePreprint
Advanced age
upin humans3
3 studies
Advanced age
upin humans3
Advanced age is linked with a higher risk of postoperative cognitive dysfunction in humans (elective neurosurgical procedures).
“Advanced age (≥65 years), low education level, intraoperative hypotension, and postoperative delirium were significant predictors of POCD”
Humanselective neurosurgical proceduresn = 150
Impact of Anesthetic Techniques on Postoperative Cognitive Dysfunction Following Neurosurgery
Annals of International medical and Dental Research
Advanced age is associated with postoperative cognitive dysfunction in humans (postoperative day 3) (P = 0.044).
“advanced age and elevated creatinine (day 3, P value = 0.044, P value = 0.008), and hypoalbuminemia (day 3, P value = 0.042; day 7, P value = 0.015) were independently associated with early POCD.”
Humanspostoperative day 3n = 125
World journal of psychiatry
advanced age raises the risk of postoperative cognitive dysfunction in humans.
“Advanced age is considered as an independent risk factor of POCD.”
Review
Inflammopharmacology
Ketamine
downin humans2upin humans1
3 studies
Ketamine
downin humans2upin humans1
Ketamine lowers the risk of postoperative cognitive dysfunction in humans.
“Additionally, there was a rise in the number of patients who developed POCD in the control group when compared to ketamine and dexmedetomidine groups (P < 0.0001); however, the ketamine and dexmedetomidine groups did not vary from one another (P = 0.747)..”
Human trialstarted 10 min before the start of surgery and continued throughout the duration of surgeryn = 90
Indian journal of anaesthesia
Ketamine lowers the risk of postoperative cognitive dysfunction in humans (geriatric anesthesia).
“low-dose ketamine (0.3-0.5 mg/kg) is neuroprotective and decreases the rate of cognitive dysfunction in certain patients”
Reviewgeriatric anesthesia0.3-0.5 mg/kg
The impact of ketamine on cognitive outcomes in geriatric anesthesia: a comprehensive review
Frontiers in psychiatry
Ketamine raises the risk of postoperative cognitive dysfunction in humans (compared with remimazolam and dexmedetomidine).
“ketamine was likely associated with an increased risk of POCD, similar to propofol, when compared to remimazolam and dexmedetomidine”
Reviewcompared with remimazolam and dexmedetomidine
Impact of Ketamine and Propofol on Cognitive Function in Elderly Patients: A Systematic Review
Cureus
Probiotics
downin humans2RR 0.47
2 studies
Probiotics
downin humans2RR 0.47
Probiotics lower the risk of postoperative cognitive dysfunction in humans (6.7% vs. 17.2%).
“POCD occurred in 6 out of 90 patients in the probiotics group and 16 out of 93 patients in the control group, and the incidence of POCD in the probiotic group was significantly lower than that in the control group (6.7% vs. 17.2%, P = 0.028).”
Human trialfrom 1 day before to 5 days after surgery
Journal of translational medicine
Probiotics lower the risk of postoperative cognitive dysfunction in humans (elective lower-extremity orthopedic surgery) (6.7% vs. 17.2%, P = 0.028).
“The incidence of POCD in the probiotic group was significantly lower than in the control group (6 of 90 patients [6.7%] vs. 16 of 93 patients [17.2%], P = 0.028).”
Human trialelective lower-extremity orthopedic surgeryorally, 2 times/day210 mgx4/dosefrom 1 day before surgery to 5 days after surgery
Journal of translational medicine
Probiotics lower the risk of postoperative cognitive dysfunction in humans (RR, 0.47 [95% CI, 0.27 to 0.81]).
“Postoperative cognitive dysfunction occurred in 12 (26.7%) of 45 patients in the probiotic group and 29 (56.9%) of 51 patients in the placebo group (RR, 0.47 [95% CI, 0.27 to 0.81]; P = 0.003, ).”
Human trialn = 96
Frontiers in aging neuroscience
Probiotics lower the risk of postoperative cognitive dysfunction in humans (undergoing elective hip or knee arthroplasty) (RR 0.47 (95% CI 0.27 to 0.81), P = 0.003).
“POCD occurred in 12 (26.7%) of 45 patients in the probiotic group and 29 (56.9%) of 51 patients in the placebo group (relative risk [RR], 0.47 [95% confidence interval [CI], 0.27 to 0.81]; P = 0.003).”
Human trialundergoing elective hip or knee arthroplastyfour capsules, twice/dayfrom hospital admission until dischargen = 96
Frontiers in aging neuroscience
Stellate ganglion block
downin humans2
2 studies
Stellate ganglion block
downin humans2
Stellate ganglion block lowers the risk of postoperative cognitive dysfunction in humans.
“As determined by the MMSE and MoCA scores, the incidence of POCD on T8 was significantly lower in the SG group, when compared to the control group (p < 0.05, ).”
Human trialtwo hours or greatern = 104
Frontiers in aging neuroscience
Stellate ganglion block lowers the risk of postoperative cognitive dysfunction in humans (postoperative day one after laparoscopic gastrointestinal surgery) (p < 0.05).
“The SGB group had a significantly lower incidence of POCD on postoperative day one (p < 0.05).”
Human trialpostoperative day one after laparoscopic gastrointestinal surgeryn = 98
Frontiers in aging neuroscience
Stellate ganglion block lowers the risk of postoperative cognitive dysfunction in humans.
“Compared with Group C, MMSE scores were significantly higher and the incidence of POCD was significantly lower at T9 and T10 in Group S (P < 0.05) (Table 5).”
Human trialn = 40
Research SquarePreprint
Stellate ganglion block lowers the risk of postoperative cognitive dysfunction in humans (elderly patients undergoing radical resection of gastrointestinal malignant tumor) (P< 0.05).
“lower incidence of POCD (P< 0.05).”
Human trialelderly patients undergoing radical resection of gastrointestinal malignant tumorn = 40
Research SquarePreprint
Neostigmine
downin humans2upin humans1OR 0.31–1.74
2 studies
Neostigmine
downin humans2upin humans1OR 0.31–1.74
Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (-22% (95% CI, -37 to -7)).
“Patients receiving neostigmine had a significantly reduced incidence of POCD compared to patients who were treated with placebo on the first day after surgery (-22%, 95% confidence interval [CI], -37 to -7)”
Human trial0.04 mg/kgn = 118
Anesthesia and analgesia
Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 0.31, 95% CI 0.15-0.63).
“administration of a higher dose (≥0.04 mg/kg) was associated with reduced POCD incidence compared to a lower dose (<0.04 mg/kg) (OR 0.31, 95% CI 0.15-0.63, p = 0.001)”
Reviewpostoperative general anesthesia with neuromuscular blockade≥0.04 mg/kg vs <0.04 mg/kg
Diagnostics (Basel, Switzerland)
Neostigmine raises the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 1.74, 95% CI 1.00-3.02).
“neostigmine was associated with a higher risk of POCD than sugammadex (OR 1.74, 95% CI 1.00-3.02, p = 0.05)”
Reviewpostoperative general anesthesia with neuromuscular blockaden = 795
Diagnostics (Basel, Switzerland)
Remimazolam
downin humans2
2 studies
Remimazolam
downin humans2
Remimazolam lowers the risk of postoperative cognitive dysfunction in humans.
“The incidence of POCD at T8 and T9 was significantly lower in Group R than Group M (P = 0.031 and P = 0.017, respectively).”
Human trialn = 70
Clinical interventions in aging
Remimazolam lowers the risk of postoperative cognitive dysfunction in humans (lower extremity fracture surgery under general anesthesia) (P = 0.031 and P = 0.017).
“significantly lower incidence of postoperative cognitive dysfunction at T8 and T9 (P = 0.031 and P = 0.017, respectively)”
Human triallower extremity fracture surgery under general anesthesia0.1 mg/kg bolus followed by 0.1 mg·kg−1·h−1
Clinical interventions in aging
Remimazolam lowers the risk of postoperative cognitive dysfunction in humans.
“At 3 days postoperative (T6) and 7 days postoperative (T7), there was no statistically significant difference (p > 0.05) in the incidence of POCD between groups R and D, even though both were lower than the incidence of POCD in group C, which was statistically significant (p < 0.05).”
Human trial
Frontiers in aging neuroscience
All 158Fewer
Trial sponsors
Company1 trial304 people
Icahn School of Medicine at Mount Sinai
3 trialsPhase 4535 people
2 trialsPhase 4125 people
Medizinische Universitaet Wien
1 trialPhase 41,332 people
The First Affiliated Hospital of Anhui Medical University
1 trialPhase 4464 people
1 trialPhase 4300 people
1 trialPhase 4300 people
The Second Affiliated Hospital of Chongqing Medical University
1 trialPhase 4298 people
Funding
19 grants since 2017National Institute on Aging$6.1MJapan Society for the Promotion of Science¥55.8MNational Cancer Institute$727K
National Cancer InstituteH. Lee Moffitt Cancer Ctr & Res Inst$727K2026–2031
Pathogenesis of Postoperative Cognitive Dysfunction
National Institute on AgingUniversity of Texas Hlth Sci Ctr Houston$724K2025–2030
Natural Science Foundation of Hunan ProvinceHunan University of Chinese Medicine2026
Treatment of postoperative cognitive dysfunction by enhancing circadian rhythm
Japan Society for the Promotion of ScienceOita University¥4.6M2025–2029
The clarify the mechanism of postoperative cognitive dysfunction
Japan Society for the Promotion of ScienceGunma University¥4.6M2023–2026
Japan Society for the Promotion of ScienceAkita University¥4.7M2023–2026
Japan Society for the Promotion of ScienceWaseda University¥4.7M2023–2026
Neuro-inflammation in Postoperative Cognitive Dysfunction: CSF and fMRI Studies
National Institute on AgingDuke University$215K2017–2023
Japan Society for the Promotion of ScienceWakayama Professional University of Rehabilitation¥3.8M2021–2024